Evidence from the King's College London Human Clinical Study
One of the hallmarks of healthy ageing is maintaining cellular energy while limiting the chronic, low-grade inflammation that develops with age. CD38 has emerged as one of the most important enzymes in longevity research because it consumes NAD+, a molecule essential for mitochondrial function, cellular energy production, DNA repair, and healthy ageing. As CD38 activity increases with age, NAD+ levels decline, contributing to many of the biological changes associated with ageing.
The DailyColours® discovery programme first identified CD38 as a key biological target during its preclinical enzyme inhibition research. DailyColours® demonstrated significant inhibition of CD38 in laboratory studies, providing the scientific rationale for evaluating this pathway in a human clinical trial.
What Did the King's College London Study Find?
Researchers at King's College London conducted a randomized, double-blind, placebo-controlled, crossover clinical trial to investigate the biological effects of DailyColours® in healthy adults. Compared with placebo, DailyColours® prevented the significant increase in circulating CD38 concentrations observed over 24 hours (p = 0.019), providing human evidence that it modulates a key biological pathway associated with healthy ageing. The findings were subsequently published in the peer-reviewed journal Antioxidants.
Why Is This Important?
CD38 has become a major focus of ageing research because increased CD38 activity is closely associated with declining NAD+ levels, mitochondrial dysfunction, chronic inflammation, and reduced cellular resilience. By translating its preclinical enzyme inhibition findings into a significant biological effect in humans, DailyColours® provided important clinical validation of its systems biology research platform.
The DailyColours® Difference
The King's College London study represents an important milestone in the DailyColours® research programme. It not only confirmed one of the key discoveries from the preclinical enzyme research but also demonstrated that a systems biology approach based on Mediterranean phytochemical diversity can produce measurable biological effects in humans. The progression from enzyme discovery to human clinical validation provides strong support for the scientific foundation underpinning the DailyColours® platform.
Key Takeaway
The DailyColours® research programme progressed from identifying CD38 as a key longevity target in preclinical enzyme studies to demonstrating significant modulation of this pathway in a randomized human clinical trial. Together, these findings provide clinical evidence that a systems biology approach inspired by the Mediterranean Diet can influence biological pathways associated with healthy ageing.